← BIOCRYST PHARMACEUTICALS INC BCRX
Market Price
$9.75
Market Cap
$2.49B
P/E Ratio
8.06
Revenue (FY 2025)
↑94.1% YoY
$874.84M
3-Yr CAGR: 47.8%
Net Income
↑396.9% YoY
$263.86M
Net Margin: 30.2%
Free Cash Flow
↑749.0% YoY
$344.90M
FCF Yield: 13.85%
EPS (Diluted)
↑381.4% YoY
$1.21
Basic: $1.26
Return on Equity
Efficiency
N/A
ROA: 1,535.7%
⚡ N/A due to negative equity (share buybacks or other)
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (BCRX)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $26.4M | — | $19.9M | $-55.1M | — | $-0.75 | — | $-53.4M | $-58.7M | — |
| FY 2017 | $25.2M | -4.4% | $16.6M | $-65.8M | -19.3% | $-0.78 | -4.0% | $-41.1M | $-41.5M | +29.4% |
| FY 2018 | $20.7M | -18.0% | $5.2M | $-101.3M | -53.9% | $-0.98 | -25.6% | $-92.6M | $-92.9M | -124.1% |
| FY 2019 | $48.8M | +136.5% | $36.9M | $-108.9M | -7.6% | $-0.94 | +4.1% | $-89.6M | $-89.9M | +3.2% |
| FY 2020 | $17.8M | -63.5% | $3.3M | $-182.8M | -67.9% | $-1.09 | -16.0% | $-137.2M | $-137.7M | -53.2% |
| FY 2021 | $157.2M | +782.4% | $97.9M | $-184.1M | -0.7% | $-1.03 | +5.5% | $-142.2M | $-144.5M | -4.9% |
| FY 2022 | $270.8M | +72.3% | $171.7M | $-247.1M | -34.3% | $-1.33 | -29.1% | $-161.8M | $-163.2M | -12.9% |
| FY 2023 | $331.4M | +22.4% | $223.2M | $-226.5M | +8.3% | $-1.18 | +11.3% | $-95.1M | $-97.3M | +40.4% |
| FY 2024 | $450.7M | +36.0% | $352.2M | $-88.9M | +60.8% | $-0.43 | +63.6% | $-52.0M | $-53.1M | +45.4% |
| FY 2025 | $874.8M | +94.1% | $796.0M | $263.9M | +396.9% | $1.21 | +381.4% | $347.4M | $344.9M | +749.0% |
Valuation
Market Price
$9.75
Market Cap
$2.49B
Enterprise Value
$2.40B
P/E Ratio
8.06
P/B Ratio
N/A
FCF Yield
13.85%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
90.98%
Operating Margin
38.98%
Net Margin
30.16%
Return on Equity (ROE)
N/A (Negative Equity)
Return on Assets (ROA)
1,535.68%
Asset Turnover
50.92x
Revenue 3-Yr CAGR
47.82%
Financial Health & Liquidity
Current Ratio
0.14
Cash Ratio
0.71
Debt / Equity
-0.000
Debt / Assets
0.000
Cash & Equivalents
$89.74M
Total Debt
N/A
Book Value / Share
$-0.47
Cash Flow Efficiency
Operating Cash Flow
$347.37M
Capital Expenditures (CapEx)
$2.47M
Free Cash Flow
$344.90M
OCF / Revenue
39.71%
FCF / Revenue
39.42%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$1.21
EPS (Basic)
$1.26
Dividends / Share
N/A
Book Value / Share
$-0.47
EPS YoY Growth
381.40%
Balance Sheet (FY 2025)
Total Assets
$17.18M
Total Liabilities
$126.41M
Stockholders' Equity
-$119.15M
Current Assets
$17.18M
Current Liabilities
$126.41M